{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:41:10Z","timestamp":1771623670532,"version":"3.50.1"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Anlotinib is a multi-target tyrosine kinase inhibitor that has been approved in China as a third-line treatment for advanced non-small cell lung cancer. It exerts anti-tumor effects by inhibiting tumor growth and tumor angiogenesis, and its toxicity also arises from this mechanism. Anlotinib can damage vascular endothelium, thereby inducing cardiovascular toxicity, which leads to hypertension, hyperlipidemia, accelerated atherosclerosis, and the initiation of atherosclerotic cardiovascular disease, ultimately resulting in life-threatening cardiovascular events. To the best of our knowledge, this study is the first case report documenting the development of hypertension, hyperlipidemia, hypothyroidism, subsequent discovery of bilateral renal artery stenosis, and acute myocardial infarction in a young patient receiving anlotinib treatment. This showed anlotinib may accelerate systemic large\/medium-sized artery atherosclerosis in the context of complex tumor therapy, causing life-threatening cardiovascular events. Besides, it highlights the necessity of regular monitoring of relevant indicators during follow-up for patients undergoing anlotinib therapy, enabling early detection of warning signs and timely intervention.<\/jats:p>","DOI":"10.3389\/fonc.2025.1719861","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T05:22:06Z","timestamp":1768540926000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Anlotinib-induced renovascular hypertension and severe coronary artery stenosis: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Yao","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v13.i6.98084","article-title":"Anlotinib-induced sick sinus syndrome: Two case reports","volume":"13","author":"Fu","year":"2025","journal-title":"World J Clin Cases"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","article-title":"Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition","volume":"70","author":"Touyz","year":"2017","journal-title":"Hypertension"},{"key":"B3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12944-023-01907-y","article-title":"Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells","volume":"22","author":"Zhu","year":"2023","journal-title":"Lipids Health Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.9041","article-title":"Anlotinib-induced acute myocardial infarction: A case report and literature review","volume":"20","author":"Liu","year":"2020","journal-title":"Exp Ther Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the new--an evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.03.024","article-title":"Association between radiation heart dosimetric parameters, myocardial infarct and overall survival in stage 3 non-small cell lung cancer treated with definitive thoracic radiotherapy","volume":"120","author":"Lee","year":"2018","journal-title":"Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2174\/1381612827666211006145141","article-title":"Anlotinib-induced hypertension: current concepts and future prospects","volume":"28","author":"Lv","year":"2022","journal-title":"Curr Pharm Des"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12473","article-title":"A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma","volume":"12","author":"Song","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12944-023-01907-y","article-title":"Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells","volume":"22","author":"Zhu","year":"2023","journal-title":"Lipids Health Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-025-10070-y","article-title":"New-onset arrhythmias in advanced lung cancer patients undergoing anlotinib treatment","volume":"25","author":"Shang","year":"2025","journal-title":"Cardiovasc Toxicol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13288","article-title":"Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma","volume":"11","author":"Jiang","year":"2020","journal-title":"Thorac Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1526337","article-title":"Anlotinib-associated pulmonary embolism in brainstem glioblastoma treatment: a case report","volume":"15","author":"Zhao","year":"2025","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241285755","article-title":"Unveiling the cardiotoxicity conundrum: navigating the seas of tyrosine kinase inhibitor therapies","volume":"31","author":"Ekram","year":"2024","journal-title":"Cancer Control"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1719861\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T05:22:06Z","timestamp":1768540926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1719861\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":16,"alternative-id":["10.3389\/fonc.2025.1719861"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1719861","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1719861"}}